Grant: Strategic Projects - Group
McGill University
$176,200.00
Advanced manufacturing technology of virus like particles for vaccination
FY 2016-17
Summary
Vaccination remains one of the most successful medical interventions to control diseases and contribute to the reduction of health care costs. Among the novel antigen presentation approaches, Virus-Like Particle (VLP) vaccines are one of the most promising approaches to respond to the constant threat of pandemic influenza strains. Among the platforms that can be used for the production of VLPs, the insect cell production platform has been garnering significant attention and acceptance by industry following the licensing of vaccines manufactured using this technology. This project uses a systems approach (both at the molecular and global levels: from gene to metabolome and from cell design to product purification) to put research on a material of interest (material systems accepted topics: virus-like particles) in the context of a manufacturing process. The work is well positioned for commercialization given the support of: Biogro Technologies, which have interest in the development of a fully defined medium for the insect cell technology platform; and Chenomx Inc., which want to develop algorithms to automate profiling of NMR spectra to make their platform suitable as a Process Analytical Technology used in biomanufacturing. More specifically, this work will address critical challenges associated with the manufacturing of enveloped VLPs using an insect cell/baculovirus expression system. The overall objective of the strategic project is to develop a robust and high-yielding insect cell culture process for the production of influenza VLPs with the specific target of large-scale industrial manufacturing. To achieve this goal: 1) a new insect cell culture expression system will be developed; 2) VLP yield will be optimized through rational media design and process intensification targeting a ten-fold increase over the current yield; 3) new purification methods and new process analytical technologies will be developed; and 4) the process and the quality attributes of the product will be documented to support technology transfer. Overall this project will contribute to building biomanufacturing capacity in Canada and will ultimately lead to Canada's ability to respond to the threat of emerging infectious diseases.
Program
Strategic Projects - Group
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
462995-2014
Name nom
Kamen, Amine
Department département
Bioengineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2014
Award amount
176200
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1569
Committee name en
Strategic Projects Selection Panel - Manufacturing
Committee name fr
Comité de sélection des projets stratégiques - Fabrication
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
3
Nb partie
3
Application title
Advanced manufacturing technology of virus like particles for vaccination
Keyword
NSERC
Application summary
Vaccination remains one of the most successful medical interventions to control diseases and contribute to the reduction of health care costs. Among the novel antigen presentation approaches, Virus-Like Particle (VLP) vaccines are one of the most promising approaches to respond to the constant threat of pandemic influenza strains. Among the platforms that can be used for the production of VLPs, the insect cell production platform has been garnering significant attention and acceptance by industry following the licensing of vaccines manufactured using this technology. This project uses a systems approach (both at the molecular and global levels: from gene to metabolome and from cell design to product purification) to put research on a material of interest (material systems accepted topics: virus-like particles) in the context of a manufacturing process. The work is well positioned for commercialization given the support of: Biogro Technologies, which have interest in the development of a fully defined medium for the insect cell technology platform; and Chenomx Inc., which want to develop algorithms to automate profiling of NMR spectra to make their platform suitable as a Process Analytical Technology used in biomanufacturing. More specifically, this work will address critical challenges associated with the manufacturing of enveloped VLPs using an insect cell/baculovirus expression system. The overall objective of the strategic project is to develop a robust and high-yielding insect cell culture process for the production of influenza VLPs with the specific target of large-scale industrial manufacturing. To achieve this goal: 1) a new insect cell culture expression system will be developed; 2) VLP yield will be optimized through rational media design and process intensification targeting a ten-fold increase over the current yield; 3) new purification methods and new process analytical technologies will be developed; and 4) the process and the quality attributes of the product will be documented to support technology transfer. Overall this project will contribute to building biomanufacturing capacity in Canada and will ultimately lead to Canada's ability to respond to the threat of emerging infectious diseases.